TY  - ADVS
AU  - Harrington,Kevin,J.
TI  - Talimogene laherparepvec: first-in-class oncolytic immunotherapy 
T2  - Immunotherapy of cancer,
PY  - 2016///
CY  - London
PB  - Henry Stewart Talks
KW  - Cancer
KW  - Immunotherapy
KW  - Drug targeting
KW  - Melanoma
KW  - Viruses
KW  - Therapeutic use
KW  - Adjuvants, Immunologic
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - CD8-Positive T-Lymphocytes
KW  - immunology
KW  - Granulocyte-Macrophage Colony-Stimulating Factor
KW  - Herpesvirus 1, Human
KW  - methods
KW  - therapy
KW  - Neoplasms
KW  - Oncolytic Virotherapy
KW  - Simplexvirus
KW  - genetics
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Contents: Causing tumour cell lysis -- Initiating a specific systemic immune response -- T-VEC as an oncolytic HSV-1 strain -- Assessing cancer immunotherapy through melanoma -- Applicability of oncolytic viral therapy to various cancers; Access restricted to subscribers
UR  - https://hstalks.com/bs/3401/
UR  - https://hstalks.com/bs/p/896/
ER  -